Skip to content

Clinical and microbiological efficacy of Lactobacillus reuteri as an adjunctive therapy to non-surgical periodontal treatment of chronic periodontitis with type 2 diabetes: a randomized controlled clinical trial

Clinical and microbiological efficacy of Lactobacillus reuteri as an adjunctive therapy to non-surgical periodontal treatment of chronic periodontitis with type 2 diabetes: a randomized controlled clinical trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2200057710
Enrollment
Unknown
Registered
2022-03-15
Start date
2022-02-28
Completion date
Unknown
Last updated
2023-11-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Periodontitis with type 2 diabetes

Interventions

Probiotics-Probiotics Group:Probiotics for the first phase and probiotics for the second
Probiotics-Control Group:Probiotics in the first stage and no intervention in the second
Control-Probiotics Group:No intervention was performed in the first phase and probiotics were administered in the second phase
Control-Control Group:None

Sponsors

The Affiliated Stomatology Hospital of Zhejiang University School of Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
35 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. Aged 35-70 years; 2. Diagnosed with type II diabetes mellitus, has been treated for at least 6 months, Hba1c =15 remaining teeth.

Exclusion criteria

Exclusion criteria: 1. Smoking or quitting for less than 5 years; 2. Other systemic diseases known to affect the progression of periodontitis (immune abnormalities, osteoporosis, a history of radiotherapy for the head and neck, etc.); 3. Periodontal treatment within 6 months; 4. Have taken antibiotics, non-steroidal anti-inflammatory drugs, immunosuppressants, hormones and other periodontal drugs within 3 months; 5. Have taken probiotic drugs within 6 months; 6. The need for prophylactic antibiotic use; 7. Pregnant and lactating patients.

Design outcomes

Primary

MeasureTime frame
Probing Depth;Microorganism;Gingival Index;Recession Depth;Clinical Attachment Loss;Bleeding of Probing;Fasting Blood Glucose;HbA1c;Gingival Crevicular Fluid IL-1ß, IL-6, TNF-a;

Countries

China

Contacts

Public ContactDing Peihui

The Affiliated Stomatology Hospital of Zhejiang University School of Medicine

phding@zju.edu.cn+86 18957108518

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026